13.61
+0.15(+1.11%)
Currency In USD
Address
100 Campus Drive
Florham Park, NJ 07932
United States of America
Phone
877 742 8466
Sector
Healthcare
Industry
Biotechnology
Employees
427
First IPO Date
October 25, 2019
| Name | Title | Pay | Year Born |
| Mr. Steven L. Basta M.B.A. | Chief Executive Officer, President & Director | 0 | 1966 |
| Mr. David A. Socks | Co-Founder & Director | 54,167 | 1975 |
| Ms. Molly Henderson CPA, MBA | Chief Financial & Business Officer | 777,763 | 1971 |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder & Chief Operating Officer | 888,897 | 1960 |
| Mr. Martin J. Gilligan | Chief Commercial Officer | 0 | N/A |
| Mr. Tom Harris | Chief Development Sciences Officer | 0 | N/A |
| Mr. Jonathan Bentley | Senior Vice President & Head of Sales | 0 | N/A |
| Mr. Paul Cocja | Chief People Officer | 0 | N/A |
| Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer | 0 | N/A |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.